Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Nusano Announces Series C Financing of Over $115M with The Wasatch Group and S32

Oct 01, 2024•over 1 year ago

Contract Type

partnership

ValenciaInformation TechnologyBiotechnologyHealth CareMedicalMedical Deviceresearch

Description

Nusano, Inc. announced a Series C financing round with funding commitments of over $115 million led by The Wasatch Group, with additional participation by S32. The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).

Company Information

Company

Nusano

Location

4669 W Lake Park Blvd

Valencia, New Mexico, United States

About

Nusano is a medical technology company that creates radioisotopes—tiny tracers used by doctors to diagnose and treat cancer and other diseases. Doctors use these tiny tracers like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use radioisotopes to target and eliminate cancer cells with precision.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Nusano's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months